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Background: The nonreceptor tyrosine kinase Src regulates multiple pathways critical to tumor proliferation,
chemoresistance, and epithelial-to-mesenchymal transition. It is robustly activated after acute oxaliplatin exposure and
in acquired oxaliplatin resistance in vitro and in vivo, but not after 5-fluorouracil (5-FU) alone. However, activation of Src
and its substrate focal adhesion kinase (FAK) in metastatic colorectal cancer treated with oxaliplatin has not been
investigated. We retrospectively evaluated the activation of Src and FAK in hepatic metastases of colorectal cancer
and correlated these findings with the clinical outcomes of patients treated with oxaliplatin.
Methods: Samples from 170 hepatic resections from patients with metastatic colorectal cancer from two cohorts were
examined by IHC for expression of Src, activated Src (pSrc), FAK, and activated FAK (pFAK). Patients in the first cohort
(120 patients) were analyzed for immunohistochemical protein expression and for survival outcomes. In the second
cohort, tissue was collected from 25 patients undergoing sequential hepatic metastasectomies (n = 50).
Results: In the first cohort, Src activation was positively correlated with pFAK expression (P = 0.44, P < 0.001). Patients
pretreated with oxaliplatin and 5-FU demonstrated increased expression of pFAK (P = 0.017) compared with patients
treated with 5-FU alone or irinotecan/5-FU. Total Src expression was associated with the number of neoadjuvant cycles
of oxaliplatin (P = 0.047). In the second cohort, pFAK expression was higher following exposure to oxaliplatin. When
patients were stratified by expression of pFAK and pSrc, an inverse relationship was observed between relapse-free
survival rates and levels of both pFAK (21.1 months, 16.5 months, and 7.4 months for low, medium, and high levels of
pFAK, respectively; P = 0.026) and pSrc (19.6 months, 13.6 months, and 8.2 months, respectively; P = 0.013). No
differences in overall survival were detected.
Conclusions: Patients administered neoadjuvant oxaliplatin demonstrated higher levels of Src pathway signaling in
hepatic metastases, a finding associated with poorer relapse-free survival. These results are consistent with prior in vitro
studies and support the idea that combining Src inhibition with platinum chemotherapy warrants further investigation
in metastatic colorectal cancer.
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The 60-kDa nonreceptor tyrosine kinase Src is among
the nine members of the Src family kinases, which regu-
late cell proliferation, migration, adhesion, invasion, dif-
ferentiation, and angiogenesis [1-3]. While Src is found
throughout all human cells [4], increased activity of this
proto-oncogene has been described in multiple solid tu-
mors, including breast, lung, pancreatic, and ovarian can-
cers [5]. Cellular stimuli induce conformational changes
that increase Src kinase activity via dephosphorylation of
residue Y530 and autophosphorylation of residue Y416 [6].
Interaction of activated Src with adjacent signaling enzymes
and cytoskeletal proteins subsequently triggers multiple
downstream pathways such as PI3K/Akt and Ras/Raf/
MAPK, which have been implicated in tumor survival and
proliferation [7].
In colorectal cancer, overexpression of the Src protein
and epigenetic changes in the tumor cell have been cor-
related with increased activity of Src kinase [3,8], which
clinically has been associated with shorter disease-free
survival in patients undergoing curative resection and
with shorter overall survival in patients with metastatic
disease [9]. Src hyperactivity also has been associated
with a more aggressive tumor phenotype through pro-
motion of epithelial-to-mesenchymal transition [10] and
through focal adhesion kinase (FAK)-mediated tumor
cell motility [11]. In addition, in vivo studies have shown
that Src activity is higher in colorectal cancer cells rela-
tive to adjacent normal colonic epithelium [12], as well
as in hepatic metastases relative to the primary colorec-
tal tumor [13].
In vivo studies for multiple solid tumors have demon-
strated that Src activity is implicated in resistance to
chemotherapy and that inhibition of Src may restore
sensitivity to chemotherapy [14-16]. Although no con-
vincing benefit for Src inhibitors as single agents in pa-
tients with refractory metastatic colorectal cancer has
thus far been reported from early-phase trials [17], pre-
clinical studies have shown that the combination of the
Src inhibitor dasatinib with oxaliplatin significantly re-
duced the volume of hepatic metastases in mice relative
to treatment with either agent alone [18]. When given in
combination with 5-FU, Src was robustly activated after
acute oxaliplatin exposure and in acquired oxaliplatin re-
sistance in vitro and in vivo, but not after 5-FU alone.
Activation of Src (denoted by phosphorylation at Y416)
and its substrate FAK (phosphorylated at Y861) in meta-
static colorectal cancer treated with oxaliplatin has thus
far not been investigated. The purpose of this study was to
retrospectively assess 170 samples from hepatic metastases
of patients with colorectal cancer to determine the activa-
tion of Src and FAK when treated with platinum-based
chemotherapy. We assessed the implication of protein/ac-
tivated protein levels on clinical outcomes. We found thatneoadjuvant oxaliplatin was associated with higher levels
of FAK activation in hepatic metastases compared with
non-oxaliplatin-based regimens, a finding associated with
poorer relapse-free survival. These results are consistent
with those of prior in vitro studies correlating oxaliplatin
exposure with activation of the Src pathway and support
the idea that combining inhibition of Src with platinum
chemotherapy warrants further investigation in patients
with metastatic colorectal cancer.
Methods
Patient demographics
The MD Anderson institutional computerized database
was reviewed in order to collect information regarding
the clinical characteristics and pathologic features of tu-
mors from patients studied in this series. Chi-squared ana-
lysis was performed to assess for differences in gender
distribution for the various cohorts, and Fisher’s exact t-
tests were employed to compare distributions of patients
according to ethnicity, site of primary tumor, histological
subtype, and tumor grade.
Tissue procurement
Two separate cohorts of patients were used for these
retrospective studies. No tissue was collected prospect-
ively. Records at our institution were screened to identify
patients with metastatic colorectal cancer treated be-
tween 12/1995 and 9/2011 who had undergone resection
for hepatic metastases. Patients analyzed either pre-
sented at initial diagnosis with metastatic disease or de-
veloped metastatic disease following a prior resection of
the primary tumor. Patients with no remaining tumor
available for immunohistochemical staining were ex-
cluded from consideration.
In the first cohort, tissue from 120 patients with meta-
static colorectal cancer was collected from hepatic
metastectomy. These patients either received no neoadju-
vant treatment, or received combination treatment with
either 5-fluorouracil and oxaliplatin (FOLFOX) or 5-
fluorouracil and irinotecan (FOLFIRI) prior to hepatec-
tomy. From each tissue block, tumor-bearing regions
were elected and placed into a tissue microarray, with the
coefficient of variation within the same resected sample
(% CVwithin) calculated to estimate the intraspecimen vari-
ation. If the % CVwithin (representative of technical variabil-
ity) was greater than the coefficient of variation between
(% CVbetween) individual patients (representative of biologic
variability), then the biopsies were flagged for reanalysis; in
most cases, one core was a clear outlier and removed from
further analysis.
In the second cohort, metastases removed from 25 pa-
tients who underwent sequential hepatic resections (con-
stituting 50 cases) were collected in a tissue microarray,
with two tumor cores and one normal liver core per case.
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resection and then had a second resection for recurrent
liver-limited disease. They had received no chemotherapy
before the first resection; between the two resections, they
had either received no chemotherapy, or received treat-
ment with either oxaliplatin (FOLFOX) or irinotecan
(FOLFIRI). All tissue was collected, stored, and studied
under approval of the Institutional Review Board at
MD Anderson.
Immunohistochemical analysis
Paraffin-embedded tissue was sliced at 8 μm thickness
prior to mounting. Paraffin was removed by heating of
the slides to 60°C for 30 minutes followed by placement
in a bath of xylene followed by a series of increasingly
diluted ethanol bath. For staining of Src and phosphory-
lated forms of Src, the slides were boiled in a pressure
cooker for 5 minutes at 125°C in a bath of Borg decloa-
ker soluation (Biocare Medical Inc.). For staining of FAK
and phosphorylated forms of FAK, the slides were placed
in a bath of EDTA buffer and boiled in a microwave
oven for 5 minutes, followed by treatment with Dako
target retrieval solution (Dako North America, Inc.) for
one hour. Peroxidase activity was blocked by incubation
with 3% hydrogen peroxide for 12 minutes. The slides were
rinsed with PBS for 3 minutes each for 3 times, followed by
a protein block solution (Cyto Q immune-diluent buffer;
Innovex) for 20 minutes at room temperature. Antibodies
were diluted in the protein block solution at the specified
dilution ratio in a volume of 50 to 100 μL and incubated at
4°C overnight. A negative control was incubated in protein
block solution without the primary antibody added. Slides
were then washed again in PBS (3 minutes × 3) followed by
treatment with the secondary antibody (Mach 4 Universal
HRP polymer, Biocare Medical Inc, or 4 +Goat anti-rabbit
biotinylated antibody, Biocare Medical Inc.). Seventy micro-
liters of diaminobenzidine (DAB) was applied for 2–10
minutes followed by rinsing after sufficient staining was
developed. Counterstaining was done with Gill’s No. 3
hematoxylin (Sigma), followed by drying and mounting
with Universal mount (Open Biosystems). Mounted slides
were visualized using a bright field microscope.
Primary antibodies utilized were anti-Src antibody (1:100,
Cell Signaling Technology), anti-phospho-Src family kinase
Y416 (1:100 to 1:500, Cell Signaling Technology), anti-FAK
antibody (1:100, Cell Signaling Technology), anti-phospho-
FAK Y861, antibody (1:100, BioSource/Invitrogen), and
anti-PTEN (DAKO). Tissue was stained with antibodies
for Src, pSrc, FAK, pFAK, and PTEN. Regions containing
tumor were identified using manual masking of tumor-
bearing regions by an Ariol automated scanning micro-
scope and image analysis system. Specimens were next
measured for quantitative protein expression with a
DAB filter. After normalization of total protein levels,immunohistochemical stains were visualized at 20× ob-
jective and were graded by automated quantitating
image analysis (Aperio Technologies, Vista, CA; U.S.A.)
using a score of 0, 1+, 2+, or 3+ according to membrane
staining intensity and completeness of the tested bio-
marker. This same scoring system was used for both
sets of tissue microarrays and thereby allows for a con-
cordance in scoring between the two series (Figure 1).
The stains were compared by the Mann–Whitney test
(first cohort) or paired Wilcoxon signed-rank test (sec-
ond cohort). Both the investigators performing the
tumor masking and the pathologist interpreting the
staining were blinded to prior treatments of the patients
whose tumors were analyzed. Pearson’s correlation coef-
ficients were calculated to assess the relationship be-
tween levels of total Src, pSrc, total FAK, and pFAK.
Mutational analysis
Samples from the first cohort of patients were analyzed to
determine whether levels of Src and FAK expression were
associated with particular mutations. DNA was extracted
using a QIAamp DNA FFPE tissue kit (Qiagen, Valencia,
CA; U.S.A.) from formalin-fixed, paraffin-embedded tissue
taken from whole mounts of the same blocks used for tis-
sue microarray analysis. DNA was next sequenced using
Sequonom MassArray mass spectrometry technology
(Sequonom, Inc., San Diego, CA, U.S.A) to assess for mu-
tations in particular point mutations including but not
limited to KRAS, NRAS, BRAF, PIK3CA, and CTNNB1
(see Additional file 1: Table S1 for full listing of genes
sequenced). Metastatic samples harboring a particular mu-
tation were compared against colorectal tumors lacking
these mutations to assess for differences in levels of
protein expression.
Survival analysis
Patients from the first cohort of 120 patients were grouped
into three groups according to levels of activated protein as
quantified by immunohistochemical staining. Those falling
within one standard deviation of the mean were classified
in the “medium” expression group, and those outside this
range were deemed to have “high” or “low” expression.
Relapse-free survival and overall survival were calculated by
group according to Kaplan-Meier methodology.
Results
Patient demographics
Among the 120 patients in the first cohort to undergo
hepatic metastectomy, 62 had received no chemotherapy
prior to resection, 20 had been treated with neoadjuvant
FOLFIRI, and 38 with neoadjuvant FOLFOX regimens.
Demographic features and clinicopathologic characteris-
tics were similar between the three groups (see Additional
file 2: Table S2). Patients undergoing chemotherapy
Figure 1 Immunohistochemistry for pSrc and pFAK in hepatic metastases from colorectal cancer. The left panels demonstrate pSrc (Y416)
staining in one patient before and after treatment with oxaliplatin chemotherapy (top and bottom, respectively). In the right panels, pFAK (Y861)
staining demonstrates a similar pattern.
Table 1 Measures of tissue microarray quality








FAK 4 18 98 12.8% 6.4%
pFAK 12 29 79 17.4% 9.8%
Src 4 16 100 16.9% 7.4%
pSrc 5 18 97 14.1% 6.3%
Key: CVbetween: coefficient of variation between mean values of the 120
individual patients; CVwithin: coefficient of variation between the two core
biopsies within a single patient’s tumor.
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10.6 weeks after their last dose of chemotherapy before
proceeding to surgery. On average, 2.2 liver metastases
(range 1–13) were resected, with the mean diameter of the
largest metastasis measuring 2.7 cm (range 0.8-10.5 cm).
No statistically significant differences for any of the above
characteristics were detected between recipients of FOL-
FOX and FOLFIRI.
Among the 25 patients in the second cohort, 8 re-
ceived 5-FU chemotherapy between sequential hepatic
resections, while 9 patients and 8 patients were treated
with irinotecan-based and oxaliplatin-based chemother-
apy regimens, respectively. Patients in this cohort re-
ceived a mean 7.9 cycles (range 1–12) between surgeries.
On average, there were 1.48 (range 1–9) hepatic im-
plants removed at the second surgery, with a mean size
in maximum diameter of 2.0 cm (range 0.3-5.0 cm). Of
note, no differences in patient characteristics were seen
between the two cohorts of 120 and 25 patients studied
(see Additional file 2: Table S2).
Tissue microarray quality
Table 1 lists the distribution of inevaluable cases, single
core biopsies analyzed, and double core biopsies analyzed
for each of the four proteins among the 120 patients in
the first cohort. Some cases were inevaluable because tis-
sue sample was lost during preparation, and other biopsies
could not be used because insufficient tumor was detected
in the sample. For all four antibodies used (Src, pSrc, FAK,
and pFAK), the coefficient of variation between sampleswas greater than the coefficient of variation of the two
core biopsies within an individual tumor (Table 1).
Immunohistochemical staining for Src, FAK, and activated
products
Correlations between Src, FAK, pSrc, and pFAK in the
first cohort of patients are listed in Table 2. A strong cor-
relation was seen between pFAK and total Src (R = 0.520,
P < 0.001), as well as between pFAK and pSrc (R = 0.438,
P < 0.001). Likewise, a strong correlation was measured
between total Src and pSrc (R = 0.692, P < 0.001), although
no correlation was noted for total FAK with either Src or
pSrc. No correlations were observed between expression
of FAK, Src, and their activated products and the number
of hepatic metastases, size of metastases, sex of the pa-
tient, or age of the patient.
In the first cohort, in patients treated with oxaliplatin, ex-
pression of pFAK in the metastases was elevated compared
Table 2 Pearson’s correlation coefficients between mean
values of antibody staining for FAK, pFAK, Src, and pSrc
(cohort 1, N = 120)
FAK pFAK Src pSrc
FAK — 0.084 0.178 0.171
pFAK 0.084 — 0.520 0.438
Src 0.178 0.520 — 0.692
pSrc 0.171 0.438 0.692 —
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Total FAK was unchanged. There was no increase in pSrc
after oxaliplatin, although there was a nonsignificant trend
toward increased total Src after oxaliplatin chemotherapy.
Total Src expression was correlated with the number of cy-
cles of chemotherapy administered (P = 0.047).
A second cohort of 25 patients who underwent
two sequential hepatic metastectomies was analyzed for
differences in activated Src and FAK expression in the
separate tumor specimens. Fifteen cases had sufficient
tissue available to compare pSrc expression, and sixteen
patient samples were evaluated to compare pFAK ex-
pression. While Src phosphorylation was quantitatively
increased after oxaliplatin, the increase did not reach
statistical significance (P = 0.13, Figure 3). However, the
levels of pFAK were significantly higher following expos-
ure to platinum chemotherapy (P = 0.03), but unchanged
after irinotecan chemotherapy or between surgical sam-
ples in which patients were not exposed to cytotoxic
chemotherapy.Figure 2 Levels of pSrc, Src, pFAK, and FAK in liver metastases treate
oxaliplatin demonstrated higher levels of pFAK expression when compared
(cohort 1, N = 120).Correlation of Src and FAK with gene mutations and
PTEN expression
Sequenom analysis was used to detect mutations for
KRAS, NRAS, beta-catenin, BRAF, and PIK3CA in the
first cohort. No relationship between the presence of
KRAS, or BRAF mutations and activated Src or FAK was
appreciated. Ten samples were found to have NRAS
mutations, and nine samples contained beta-catenin mu-
tations; six samples carried both. For patients with
NRAS-mutant tumors, decreased proportions of pSrc/
Src (0.94 vs. 0.74, P = 0.006) and pFAK/FAK (1.01 vs.
0.55, P < 0.001) were detected relative to their wild-type
tumors (see Additional file 3: Table S3); likewise, signifi-
cantly lower ratios of pSrc/Src (0.94 vs 0.69) and pFAK/
FAK (1.01 vs. 0.56) were associated with beta-catenin mu-
tations (P < 0.001 for both). Levels of PTEN protein ex-
pression were not significantly correlated with FAK, Src,
pFAK, and pSrc when quantified using immunohisto-
chemical analysis, although a trend between PTEN expres-
sion and total FAK expression was observed (P = 0.054).Survival outcomes according to pSrc and pFAK expression
In the first cohort, median relapse-free survival were
21.1 months, 16.5 months, and 7.4 months, for the low-,
medium-, and high-pFAK-expression groups, respectively
(P = 0.003, Figure 4); similarly, median relapse-free sur-
vival durations were 19.6 months, 13.6 months, and
8.2 months for low, medium, and high expression levels of
pSrc, respectively (P = 0.013). No significant differences ind with various chemotherapeutic regimens. Patients exposed to
to patients exposed to a regimen containing irinotecan or 5-FU alone
Figure 3 Analysis of pSrc and pFAK expression in sequential
liver metastases resected from the same patients. Patients were
treated with no chemotherapy before the first resection and either
with an oxaliplatin-based regimen, an irinotecan-based regimen, or
no chemotherapy between resections (cohort 2, N = 15 for pSrc and
N = 16 for pFAK). Each pair of points represents a single patient.
Patients exposed to oxaliplatin demonstrated an increased in
activated pFAK and a trend towards increased pSrc that was not
observed in the patients who received no chemotherapy or an
irinotecan-based regimen.
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level groups for either pFAK or pSrc (Figure 5).
Discussion
In this study, evidence of upregulated signaling of the
Src pathway was observed in hepatic metastases after
oxaliplatin-based chemotherapy among patients withFigure 4 Relapse-free survival according to relative expression of pFA
and pSrc, respectively, demonstrated shorter periods of relapse-free survivacolorectal cancer. Not only did we detect this correlation
for oxaliplatin (and not for irinotecan or for 5-FU only
based regimens) within a cohort of 120 patients treated
with different neoadjuvant therapies prior to resection of
liver metastases, but we also confirmed these results in an
additional cohort of 25 patients who underwent sequential
hepatic metastasectomies. In both groups, higher levels of
pFAK, the activated target of Src, were seen after exposure
to oxaliplatin. Prior in vivo work has demonstrated in-
creased Src phosphorylation in mice after treatment with
oxaliplatin. Our findings are the first to confirm this effect
in human specimens, here among resected liver metasta-
ses. In addition, increased Src signaling, with pFAK ex-
pression levels as a surrogate, are associated with worse
relapse-free survival. The results generated here raise the
hypothesis that pFAK may serve as a prognostic bio-
marker in the future for patients being treated for meta-
static colorectal cancer.
Here, we show a strong correlation in tissue samples
between activated FAK and expression of both total Src
and activated Src. The only recognized mediator of FAK
phosphorylation at Y861 is Src, so this epitope is an ex-
cellent, specific indicator of Src kinase activity. The
demonstration in our study of a tight correlation of Src
activity and pFAK (P < 0.00001) supports the clinical
relevance of this relationship. The performance of the
pFAK antibody provided greater dynamic range and
staining properties compared with the other three anti-
bodies tested, suggesting that it would be an optimal
biomarker for future studies of Src activity. In contrast,
the antibody recognizing Y416 on Src also recognizes
the corresponding epitope on other members of the Src
family – such as Fyn, Lyn, and Yes – which can be over-
expressed in colon cancer [19-21]. Activated Src may
serve as an inferior, less-sensitive biomarker for Src sig-
naling in colorectal cancer specimens.
Prior in vitro data have shown that oxaliplatin acti-
vates Src via reactive oxygen species intermediates and
that Src activation is a mechanism of oxaliplatin resist-
ance [18]. These experiments prompted the exploration
of the relationship between oxaliplatin administrationK and pSrc (cohort 1, N = 120). Patients with higher levels of pFAK
l.
Figure 5 Overall survival according to relative expression of pFAK and pSrc (cohort 1, N = 120). A non-significant trend towards worse
overall survival was noted in those patients with higher levels of pFAK and pSrc.
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specimens of metastatic colorectal cancer. We show in
two cohorts that patients treated with oxaliplatin have
tumors with higher levels of activated pFAK relative
to untreated patients or patients administered other neo-
adjuvant regimens. There was a trend toward increased
total Src expression with extended duration of oxalipla-
tin treatment in the larger cohort, but changes in pSrc
did not reach statistical significance. While this discord-
ance is likely due to antibody specificity, there may also
be differences in the sensitivity of the two different
phosphorylated residues to phosphatases present during
the fixation process or differences in the temporal dynam-
ics of chronic Src and FAK activation after the several-
week chemotherapy washout prior to surgery [22].
Because the use of freshly fixed paraffin tumor has
technical limitations, we took steps to minimize the im-
pact of these concerns, including optimization of re-
agents and staining conditions, and use of freshly cut
sections for the respective tissue microarrays. In similar
experiments, phosphoepitopes have been shown to be con-
served in formaldehyde-fixed, paraffin-embedded tissue,
with phosphorylated Akt levels using similar methodology
studied as markers for PI3K/Act activation in metastatic
colorectal tissues [23]. In addition, we recognize that these
results should not be yet generalized to all metastatic colo-
rectal carcinomas, as our studies were performed only in
liver metastases.
Specimens were also assessed for any association be-
tween protein/activated protein levels and various muta-
tions. No association was found for either KRAS or
BRAF – two genes that, when mutated, have important
therapeutic and/or prognostic implications in metastatic
colorectal cancer; however, statistically significant lower
Src and FAK activity was detected in the presence of
NRAS and CTTNB1 mutations (P < 0.01 for all). The
clinical implication of this association is unclear, as
NRAS mutations in metastatic colorectal cancer have
not been associated with relevant clinical or pathologic
features in prior population-based studies among pa-
tients treated with oxaliplatin [24]. In our cohort, both
NRAS (N = 10) and CTTNB1 (N = 9) mutations wererare, and six patients harbored both mutations. However,
in a larger set at our institution of 246 patients with
metastatic colorectal cancer with only mutation data
available, a pattern of dual NRAS/CTTNB1 mutations
could not be confirmed.
Activation of Src has been implicated as a mechanism
of cytotoxic chemotherapy resistance in human pancre-
atic cell lines [15]. When grouped according to relative
levels of pFAK expression, patients with higher levels of
pSrc and pFAK were noted to have a shorter recurrence-
free survival (P = 0.013 and P = 0.0026, respectively).
Similarly, a trend toward a shorter overall survival was
noted in the patients with greater expression of the acti-
vated kinases. Although statistical significance was not
reached, neoadjuvant oxaliplatin has been shown to up-
regulate Src pathway activation, and any detriment in
overall survival caused by activation of these signal trans-
duction pathways in generating chemoresistance may be
confounded by the survival benefit of neoadjuvant oxali-
platin in the treatment of metastatic colorectal cancer
[25]. Therefore, relapse-free survival may serve as a more
informative endpoint when using pSrc and pFAK as bio-
markers in the future. Nonetheless, while the immediate
clinical applicability of these markers is limited, these re-
sults provide a useful insight into the biology of liver me-
tastases and should be considered in future attempts to
develop a patient selection marker for this population.Conclusions
In summary, prior in vitro studies have shown that cellu-
lar stress arising from reactive oxygen species following
oxaliplatin exposure upregulate Src activation and that
chronic Src activation may be one mechanism of resist-
ance to oxaliplatin in metastatic colorectal cancer. Here
we report that Src signaling is elevated in patients admin-
istered oxaliplatin for neoadjuvant treatment of metastatic
colorectal cancer metastases. These findings affirm the im-
portance of Src-mediated signal transduction in the biol-
ogy of chemoresistant colorectal cancer and suggest that
blocking this pathway with Src inhibitors warrants contin-
ued consideration in clinical trials.
Kopetz et al. BMC Cancer 2014, 14:660 Page 8 of 8
http://www.biomedcentral.com/1471-2407/14/660Additional files
Additional file 1: Table S1. List of specific point mutations assessed by
Sequonom MassArray mass spectrometry.
Additional file 2: Table S2. Associations (A) between the cohorts of
patients studied in the two microarrays and (B) according to the
preoperative chemotherapy administered for patients in the first cohort
reveal no differences in patient characteristics.
Additional file 3: Table S3. Associations between mutation status and
relative levels of activated Src and FAK.
Abbreviations
5-FU: 5-fluorouracil; FAK: Focal adhesion kinase; pSrc: phosphorylated Src;
pFAK: phosphorylated focal adhesion kinase; FOLFOX: 5-fluorouracil and
oxaliplatin; FOLFIRI: 5-fluorouracil and irinotecan; CV: Coefficient of variation;
PBS: Phospho-buffered saline.
Competing interests
The authors declare no competing financial or non-financial interests.
Authors’ contributions
SK designed the experiments, drafted the IRB protocol, performed the
statistical analysis, and assisted with drafting the manuscript. VM assisted
with data and statistical analysis and drafted the manuscript. NP collected
and prepared tissue samples and performed immunostains on collected
tissue. MO assisted with statistical analysis and manuscript preparation. ZJ
consented patients for tissue collection and assisted with statistical analysis.
DM carried out pathologic analyses of stained tissue specimens. PE assisted
with study design. GG conceived the study design and gave final approval
of the manuscript for submission. All authors read and approved the
final manuscript.
Acknowledgements
The authors acknowledge the support of the Biospecimen Extraction Facility
at the University of Texas – MD Anderson Cancer Center for assistance in
histological processing and DNA collection (NCI # P30 CA016672). The
authors would like to thank Sunita Patterson in the Department of Scientific
Publications at The University of Texas MD Anderson Cancer Center for her
helpful editorial comments on this article. Research funding was provided by
AstraZeneca. The research was also supported in part by the MD Anderson
Cancer Center Support Grant (CA016672) from the National Institutes of Health.
Author details
1Department of Gastrointestinal Medical Oncology, The University of Texas
MD Anderson Cancer Center, Houston, TX, USA. 2Department of Cancer
Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX,
USA. 3Department of Genitourinary Medical Oncology, The University of
Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0018-4,
Houston, TX 77030, USA. 4Department of Pathology, The University of Texas
MD Anderson Cancer Center, Houston, TX, USA. 5AstraZeneca, Wilmington,
Delaware, USA.
Received: 22 January 2014 Accepted: 22 August 2014
Published: 10 September 2014
References
1. Taylor SJ, Shalloway D: Src and the control of cell division. Bioessays 1996,
18(1):9–11.
2. Frame MC: Newest findings on the oldest oncogene; how activated src
does it. J Cell Sci 2004, 117(Pt 7):989–998.
3. Yeatman TJ: A renaissance for SRC. Nat Rev Cancer 2004, 4(6):470–480.
4. Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases.
Annu Rev Cell Dev Biol 1997, 13:513–609.
5. Summy JM, Gallick GE: Src family kinases in tumor progression and
metastasis. Cancer Metastasis Rev 2003, 22(4):337–358.
6. Roskoski R Jr: Src kinase regulation by phosphorylation and
dephosphorylation. Biochem Biophys Res Commun 2005, 331(1):1–14.
7. Levin VA: Basis and importance of Src as a target in cancer. Cancer Treat
Res 2004, 119:89–119.8. Dehm SM, Bonham K: SRC gene expression in human cancer: the role of
transcriptional activation. Biochem Cell Biol 2004, 82(2):263–274.
9. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE: Activation
of Src kinase in primary colorectal carcinoma: an indicator of poor
clinical prognosis. Cancer 2002, 94(2):344–351.
10. Avizienyte E, Brunton VG, Fincham VJ, Frame MC: The SRC-induced
mesenchymal state in late-stage colon cancer cells. Cells Tissues Organs
2005, 179(1–2):73–80.
11. Brunton VG, Ozanne BW, Paraskeva C, Frame MC: A role for epidermal
growth factor receptor, c-Src and focal adhesion kinase in an in vitro
model for the progression of colon cancer. Oncogene 1997, 14(3):283–293.
12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,
Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R,
Kabbivavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin
for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335–2342.
13. Talamonti MS, Roh MS, Curley SA, Gallick GE: Increase in activity and level
of pp60c-src in progressive stages of human colorectal cancer. J Clin
Invest 1993, 91(1):53–60.
14. Griffiths GJ, Koh MY, Brunton VG, Cawthorne C, Reeves NA, Greaves M, Tilby
MJ, Pearson DG, Ottley CJ, Workman P, Frame MC, Dive C: Expression of
kinase-defective mutants of c-Src in human metastatic colon cancer cells
decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.
J Biol Chem 2004, 279(44):46113–46121.
15. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE: Inhibition of SRC tyrosine
kinase impairs inherent and acquired gemcitabine resistance in human
pancreatic adenocarcinoma cells. Clin Cancer Res 2004, 10(7):2307–2318.
16. George JA, Chen T, Taylor CC: SRC tyrosine kinase and multidrug
resistance protein-1 inhibitions act independently but cooperatively to
restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
Cancer Res 2005, 65(22):10381–10388.
17. Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S, Sleckman
BG, Taber D, Vokes EE, Stadler WM, Kindler HL: Dasatinib in previously
treated metastatic colorectal cancer: a phase II trial of the University of
Chicago phase II consortium. Invest New Drugs 2012, 30(3):1211–1215.
18. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP,
Abbruzzese JL, Ellis LM, Chandra J, Gallick GE: Synergistic activity of the
SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma
cells is mediated by oxidative stress. Cancer Res 2009, 69(9):3842–3849.
19. Park J, Meisler AI, Cartwright CA: c-Yes tyrosine kinase activity in human
colon carcinoma. Oncogene 1993, 8(10):2627–2635.
20. Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W: pp60c-src
activation in human colon carcinoma. J Clin Invest 1989, 83(6):2025–2033.
21. Han NM, Curley SA, Gallick GE: Differential activation of pp 60(c-src) and
pp 62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer
Res 1996, 2(8):1397–1404.
22. Kypta RM, Goldberg Y, Ulug ET, Courtneidge SA: Association between the
PDGF receptor and members of the src family of tyrosine kinases. Cell
1990, 62(3):481–492.
23. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci
E, Fuchs CS, Ogino S: Phosphorylated AKT expression is associated with
PIK3CA mutation, low stage, and favorable outcome in 717 colorectal
cancers. Cancer 2011, 117(7):1399–1408.
24. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ,
Fuchs CS, Haigis KM, Ogino S: NRAS mutations are rare in colorectal
cancer. Diagn Mol Pathol 2010, 19(3):157–163.
25. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P,
Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D,
Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W,
Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research
UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen
Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal
Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive
(FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus
surgery alone for resectable liver metastases from colorectal cancer
(EORTC intergroup trial 40983): a randomised controlled trial.
Lancet 2008, 371(9617):1007–1016.
doi:10.1186/1471-2407-14-660
Cite this article as: Kopetz et al.: Src activity is modulated by oxaliplatin
and correlates with outcomes after hepatectomy for metastatic
colorectal cancer. BMC Cancer 2014 14:660.
